



IMMUNOPRECISE ANTIBODIES

Jefferies Healthcare Conference 2023

Engineered for the race

Solving the Information Integration Dilemma

"The only way to discover the limits of the possible is to go beyond them into the impossible." - Arthur C. Clarke

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies LTD. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Further information on risks and uncertainties may be found in the Company’s Management Discussion & Analysis which may be obtained from SEDAR at www.sedar.com and SEC at www.sec.gov.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The Future of Drug Discovery is Language

- Artificial intelligence meets biology
- Revolutionizing systems biology
- Compelling and concrete evidence

The Challenge

The Information Integration Dilemma – exponential growth of biological data

- Massive, diverse biological datasets
- Issue of fragmentation
- The Information Integration Dilemma explained

Our Solution


Introducing LENS^{ai}™ and HYFTs[®] – BioStrand's groundbreaking solution to the Information Integration Dilemma

- The conception of HYFTs
- LENS^{ai} – the AI-driven software
- Bridging the gap between structure and function




Revolutionary data silo integration
and optimization

Unstructured data




Structured data



Sequence data




Protein structure data




</>


Unparalleled LENS^{ai} technology



Powered by HYFT Technology

Powerful real-time
infinite scalable data insight





Decoding HYFTs

HYFTs - The 'alphabet' of biological function, bridging the gap between structure and function



- Patented technology
- Universal patterns throughout the biosphere
- Finite and indexed for ultra-scalability and speed, low energy
- Reshape the landscape of therapeutic Ab discovery

Blending Expertise
Function-First B Cell[®]:
enriching HYFTs and
powering active
learning loops

- A powerful combination — wet lab and *in silico*
- #1 ranked CRO wet lab¹
- High-quality antibody sequence data
- Continuous enrichment of HYFTs





LENS^{ai} Integrated Intelligence Technology


Case studies:

Real-world evidence of LENS^{ai} solving drug discovery and clinical challenges.

Business impact: challenging the transgenic market


Case study: Integration of humanization and immunogenicity analysis
A **scalable** process that will enable early triaging of immunogenic clones

Case study – chicken antibody humanization



Affinity of humanized variants

Humanized variants vs reference clinical mAbs




Business case

Program design	IPA humanization	Transgenics
Immune system	++++	++
Fee structure	Fee-for-service	Royalties, licenses, milestones
Overall cost	Low	Very high

Business impact: leveraging HYFT's to streamline lead identification


Case study: Integrated *in silico* workflow from literature to library screening

NLP derived knowledge graph of > 25 billion association



Molecular dynamics

***In silico* verification of 10 enzyme inhibitors from the biosphere**



In-silico analysis validated by wet lab confirmation

Lens^{ai} effectively reduced the screening requirements of the program from >250,000 -> 10

Strategically Built

We are designed at our core to tackle big pharma's most significant discovery challenges

Accelerating Antibody
Discovery for
Challenging Targets

Efficient Program Design
and Hypothesis
Generation

Validation and
Benchmarking of Lead
Candidates

Saving Time and
Resources

Development of Safer
Therapies

Increased Drug
Development Efficiency

Greater Scalability

Reducing Reliance on
Animal Models

Fostering Precision
Medicine



Program
Design


Target
Identification

Lead
Discovery

Commercialization and Applications

Commercialization pathways unveiled by LENS^{ai} and HYFTs technology

- Drug discovery *in silico*
- Data management solutions (SAAS)
- Biomarker discovery
- Early disease detection and personalized medicine



The Impact

Unlocking new frontiers:

The impact of solving the Information Integration Dilemma

- Personalized medicine
- Prevent, or target root cause, disease
- *In silico, de novo* therapeutics

The Future

Redefining biotherapeutics: The exciting journey ahead

- Patented HYFT technology innovation
- Paving the way forward with diverse business offering — the HUB of Biotherapeutic Intelligence
- Increasing demand for novel therapeutics
- Opportunity to participate in ground-breaking scientific progress
- Extensive potential for return on investment

Thank you

Join the revolution

Contact:

ir.ipatherapeutics.com | investors@ipatherapeutics.com | NASDAQ:IPA

The HUB of Biotherapeutic Intelligence™

©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of BioStrand, BV. LENS[®] and HYFTS are trademarks of BioStrand, BV.



IMMUNOPRECISE ANTIBODIES